Medical Care Technologies Inc. (OTC PINK:MDCE) Expands Development of Consumer-Grade AI Pre-Health Screening Tools Focused on Early Detection

Medical Care Technologies (OTC PINK: MDCE) is expanding development of consumer-grade AI pre-health screening mobile apps to detect early warning signs of serious conditions and prompt timely medical follow-up.

Rhea-AI Summary

Medical Care Technologies (OTC PINK: MDCE) is expanding development of consumer-grade AI pre-health screening mobile apps to detect early warning signs of serious conditions and prompt timely medical follow-up.

The initiative builds on MDCE's prior work in early melanoma detection and broadens its AI models to assess dermatology (skin lesions), ocular health markers, and lifestyle and health-behavior risk trends. The tools are described as deep-learning models trained on medical datasets and designed to provide consumer-friendly preliminary screening insights via mobile devices.

Management emphasizes early detection and aims to make proactive screening technology widely accessible from smartphones.

Argus Dec 2 session

+66.67% close to close Open Argus

Details

News Market Reaction – MDCE

On Dec 2, the day this news came out, MDCE closed 66.67% above the previous close.

Data tracked by StockTitan Argus for the Dec 2 session.

Market Context

On Dec 2, the day this news came out, the stock closed 66.7% above the previous close. A strong posi...

Analysis

On Dec 2, the day this news came out, the stock closed 66.7% above the previous close. A strong positive reaction aligns with MDCE’s ongoing shift toward AI-driven consumer health tools. The company has repeatedly highlighted AI initiatives, from wellness apps to melanoma detection and today’s broader pre-health screening focus. Historical AI-tagged news produced an average move of 11.67%, though past reactions have been mixed. Investors would have weighed execution risks, app adoption, and the company’s ability to translate its AI roadmap into sustained revenue growth.

Historical Context

5 past events · Latest: Dec 10

5 events

1. Dec 10

   Subsidiary milestone

   24h Move

   -16.7%

   Real Game Used hit AI-driven authentication milestone for premium memorabilia.

2. Dec 09

   Partnership / structure

   24h Move

   -14.3%

   Share structure stabilization and new tech partnership amid rising investor activity.

3. Dec 08

   AI dermatology tech

   24h Move

   +0.0%

   Integration of Google-backed dermatology model into wound and skin app.

4. Dec 05

   Reg A completion

   24h Move

   +40.0%

   Conclusion of Regulation A offering, shifting focus to launches and AI innovation.

5. Dec 04

   AI strategy update

   24h Move

   +0.0%

   Acceleration toward AI health and wellness apps supported by subsidiaries.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pre-health screening, deep-learning models, ocular health markers

3 terms

pre-health screening medical

"consumer-grade AI pre-health screening mobile applications designed to help"

Pre-health screening is a set of medical checks and questionnaires performed before someone joins a study, receives a treatment, returns to work, or uses a health-related product. For investors, it matters because these screenings determine eligibility, catch safety issues early, can reveal hidden costs or delays, and influence regulatory approval and liability risk—like a gatekeeper that affects timelines, enrollment rates, and overall project viability.

deep-learning models technical

"next wave of consumer applications integrates deep-learning models trained on medical"

Deep-learning models are computer programs that learn to recognize complex patterns by processing large amounts of data through many stacked layers, somewhat like several teams passing and refining information. For investors, they matter because they can enable faster automation, better product features, cost savings and new revenue opportunities — but they also bring upfront computing costs, data and talent needs, and potential regulatory or ethical risks that can affect a company’s value.

ocular health markers medical

"assess early-risk indicators related to:Dermatology and skin-lesion irregularitiesOcular health markersLifestyle"

Ocular health markers are measurable signs and test results—such as clarity of vision, eye pressure readings, tear production, or imaging findings—that indicate how well an eye is functioning or whether disease is present. Investors care about these markers because they often determine whether a drug, device or treatment shows benefit in clinical trials, gains regulatory approval, or will be adopted by clinicians and patients; think of them as dashboard lights that drive market outcomes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MESA, ARIZONA / ACCESS Newswire / December 2, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) announced today that the company is expanding its development efforts into a new generation of consumer-grade AI pre-health screening mobile applications designed to help identify early warning signs of serious health conditions and encourage timely medical intervention.

This initiative builds upon MDCE's previously announced breakthrough in early melanoma detection. The company is now leveraging that technological foundation to broaden its AI capabilities across multiple high-risk categories, creating accessible tools that support individuals before symptoms become critical.

Advancing At-Home Early Detection

MDCE's next wave of consumer applications integrates deep-learning models trained on medical datasets to assess early-risk indicators related to:

• Dermatology and skin-lesion irregularities

• Ocular health markers

• Lifestyle and health-behavior risk trends

These tools are being engineered to provide consumer-friendly, preliminary screening insights that can help users recognize potential issues earlier and seek professional evaluation when appropriate.

"Early detection saves lives, and our goal is to make that proactive technology available to everyone," said Marshall Perkins III, CEO of Medical Care Technologies Inc. "We are fully committed to developing consumer-grade AI tools that deliver early health insights right from a mobile device."

---

About Medical Care Technologies Inc. (MDCE)

Medical Care Technologies Inc. (OTC PINK: MDCE) is committed to developing AI-driven technologies that advance preventive healthcare and consumer health intelligence. The company focuses on artificial intelligence applications spanning dermatology, ocular health, neurological tracking, wellness analytics, diet/nutrition and early-risk detection tools.

Websites: www.medicalcaretechnologies.com | www.mdcestock.com

---

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially from those described. The company undertakes no obligation to update or revise forward-looking statements except as required by law.

---

Contact:

Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com

SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Medical Care Technologies (MDCE) announce on December 2, 2025 about AI screening?

MDCE announced expansion of development for consumer-grade AI pre-health screening mobile apps to identify early warning signs across multiple high-risk categories.

Which health areas will MDCE's new AI mobile apps assess for early risk?

The apps are being developed to assess dermatology (skin-lesion irregularities), ocular health markers, and lifestyle and health-behavior risk trends.

How does MDCE plan to build on its prior technology for these apps?

MDCE is leveraging its previously announced breakthrough in early melanoma detection as a foundation to broaden AI capabilities across other risk categories.

Will MDCE's AI apps provide medical diagnoses or preliminary screening insights?

The company says the tools are engineered to provide consumer-friendly preliminary screening insights to help users recognize potential issues and seek professional evaluation when appropriate.

What technology underpins MDCE's consumer screening tools?

MDCE describes integrating deep-learning models trained on medical datasets into mobile applications to assess early-risk indicators.

What is MDCE's stated goal for these AI pre-health tools?

MDCE's stated goal is to make proactive early-detection technology available to everyone via mobile devices to help prompt timely medical intervention.